Coverage / PPCB / Trade Card

PPCB

Propanc Biopharma Inc

SPECULATIVE BUY Analysis generated 2026-10-28 Market data as of 2026-11-12 Market data 3 days old USD 1.92 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
42

Position levels

Currenttoday
USD 1.92
Buy <=wait / entry
USD 1.33
Trim >=take some off
USD 3.00
Thesis breakFailure to obtain regulatory authorisation and sufficient funding for Phase 1b, ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case8%100 / 1008.0
Base case48%62 / 10029.8
Bear case44%10 / 1004.4
Weighted conviction42 / 100 - SPECULATIVE BUY

Top risks

  • No hard catalysts such as contract wins, supply agreements, M&A or licensing deals evidenced
  • Preclinical data published on PRP reprogramming chemotherapy-resistant pancreatic cancer cells
  • FY26 financial results with EPS of ($17.62) and $832K cash at year-end
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n